XSTO
SUBGEN
Market cap5mUSD
Nov 03, Last price
0.03SEK
1D
4.24%
1Q
-34.85%
IPO
-99.68%
Name
Aegirbio AB
Chart & performance
P/E
—
P/S
554.31
EPS
—
Vol. 1Y
239.45%
Shs. 5Y
—
Rev. 5Y
503.67%
Div Yld LY
—
Div Yld TTM
—
Revenues
92k
-94.61%
Net income
-60m
L-83.55%
CFO
-42m
L-14.40%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
AegirBio AB (publ) is a diagnostics firm established in 2019 in Lund, Sweden. The company specializes in developing and commercializing tests primarily aimed at monitoring the dosage of biological drugs. Their efforts are concentrated on therapeutic drug monitoring for biologic therapies across various conditions, including multiple sclerosis, different types of cancer, and autoimmune diseases. Among their offerings are moNATor, a pioneering laboratory test designed for dose monitoring in multiple sclerosis for both medical professionals and patients, and Viraspec, a saliva-based test kit for COVID-19 detection.
Key people
Marco Witteveen
Chief Executive Officer, Executive Director · since 2023
Vicki Johnson
Interim Chief Financial Officer · since 2024
Vasiliki Fragkou
Chief Operating Officer · since 2023
William Ferenczy
Independent Director · since 2024
Fredrik Haglund
Independent Director · since 2020
Michael Schwartz
Independent Director · since 2024
Jens Umehag
Independent Chairman of the Board · since 2024
William Vickery
Independent Director · since 2022
Headquarters & legal address
Drottninggatan 32
Stockholm, AB 111 51
SE
Stockholm, AB 111 51
SE
Address
Scheelevagen 27
Lund, M 223 63
SE
Lund, M 223 63
SE
Previous name
Magnasense AB
Previous name
AegirBio AB
Valuation
Title SEK in thousands, except ratios and share amounts | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | |
| Income | |||||
Revenues | |||||
Cost of revenue | |||||
Unusual Expense (Income) | |||||
NOPBT | |||||
NOPBT Margin | |||||
Operating Taxes | |||||
Tax Rate | |||||
NOPAT | |||||
Net income | |||||
Dividends | |||||
Dividend yield | |||||
Proceeds from repurchase of equity | |||||
BB yield | |||||
| Debt | |||||
Debt current | |||||
Long-term debt | |||||
Deferred revenue | |||||
Other long-term liabilities | |||||
Net debt | |||||
| Cash flow | |||||
Cash from operating activities | |||||
CAPEX | |||||
Cash from investing activities | |||||
Cash from financing activities | |||||
FCF | |||||
| Balance | |||||
Cash | |||||
Long term investments | |||||
Excess cash | |||||
Stockholders' equity | |||||
Invested Capital | |||||
ROIC | |||||
ROCE | |||||
| EV | |||||
Common stock shares outstanding | |||||
Price | |||||
Market cap | |||||
EV | |||||
EBITDA | |||||
EV/EBITDA | |||||
Interest | |||||
Interest/NOPBT | |||||